BPL-003 Phase 2a Data Published, Shows Rapid & Durable Antidepressant Effects; Phase 3 On Track for Q2
ATAI has more than doubled off its 52-week low of $1.15.
Summary
Atai Beckley announced the peer-reviewed publication of positive Phase 2a data for its BPL-003 program in the Journal of Psychopharmacology. The data demonstrated rapid and durable antidepressant effects in patients with treatment-resistant depression (TRD), with a mean 12.6-point reduction in MADRS scores by Day 2, sustained over 12 weeks, and high response and remission rates. This publication provides significant scientific validation for the BPL-003 program, which holds Breakthrough Therapy Designation. While the Phase 3 initiation timeline was previously announced, the detailed peer-reviewed data adds crucial credibility and de-risks the asset. Investors will now focus on the planned initiation of the Phase 3 program in Q2 2026.
At the time of this announcement, ATAI was trading at $3.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $1.15 to $6.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.